• Illumina reported a return to profitability in its second-quarter results ended June 29, 2025, with net income of US$235 million despite revenues decreasing to US$1,059 million from US$1,112 million a year earlier, and also raised its fiscal 2025 earnings guidance to forecast a smaller revenue decline.
• The company completed its previously announced share repurchase program and launched the updated TruSight Oncology 500 assay, highlighting a dual focus on capital returns and ongoing product innovation within cancer research.
• We will now explore how Illumina’s renewed profitability and upgraded guidance may influence its investment narrative moving forward.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Illumina Investment Narrative Recap

To be a shareholder in Illumina, you need to believe in the expanding role of clinical genomics, particularly cancer and genetic testing, as a foundational part of modern healthcare. While Illumina’s return to profitability and improved earnings guidance offer short-term confidence, these do not materially change the biggest near-term catalyst: increased adoption in clinical markets. However, persistent uncertainty around U.S. research funding remains the largest risk, with limited impact from the recent news on this front.

Among the key recent announcements, the launch of TruSight Oncology 500 version 2 stands out as directly aligned with the clinical adoption catalyst. Enhanced workflow, broader genomic profiling capabilities, and improved compatibility reflect Illumina’s efforts to serve fast-growing clinical segments, where consistent innovation plays a crucial role in driving both short- and longer-term demand for sequencing platforms.

But on the risk side, investors should also be aware that worsening funding constraints in key research markets could...

Illumina's narrative projects $4.8 billion revenue and $862.5 million earnings by 2028. This requires 3.6% yearly revenue growth and a decrease in earnings of $437.5 million from $1.3 billion today.

Uncover how Illumina's forecasts yield a $114.00 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community range from US$86.26 to US$157.43 per share, showing a broad spectrum of opinions. With Illumina’s fortunes closely tied to ongoing clinical adoption, it’s clear market participants interpret future prospects quite differently, explore these varied viewpoints for a fuller picture.

Explore 5 other fair value estimates on Illumina - why the stock might be worth 11% less than the current price!

Build Your Own Illumina Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Illumina research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.